SIMILAR PATTERNS OF AMINO ACIDS FOR 5YU9_B_1E8B1101_1

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	GLY A 202 VAL A 209 ALA A 220 ASP A 276 LEU A 321 ASP A 332	None	0.75A	5yu9B-1k9aA: 30.1	5yu9B-1k9aA: 12.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1py5	TGF-BETA RECEPTOR TYPE I (Homo sapiens)	PF00069 (Pkinase) PF08515 (TGF_beta_GS)	7	GLY A 212 VAL A 219 ALA A 230 LEU A 278 ASP A 290 LEU A 340 ASP A 351	None PY1 A 700 ( 4.7A) PY1 A 700 (-3.5A) PY1 A 700 (-3.8A) None PY1 A 700 (-4.4A) PY1 A 700 (-2.7A)	0.82A	5yu9B-1py5A: 24.6	5yu9B-1py5A: 11.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1py5	TGF-BETA RECEPTOR TYPE I (Homo sapiens)	PF00069 (Pkinase) PF08515 (TGF_beta_GS)	7	GLY A 212 VAL A 219 ALA A 230 LYS A 232 ASP A 290 LEU A 340 ASP A 351	None PY1 A 700 ( 4.7A) PY1 A 700 (-3.5A) PY1 A 700 (-3.9A) None PY1 A 700 (-4.4A) PY1 A 700 (-2.7A)	0.97A	5yu9B-1py5A: 24.6	5yu9B-1py5A: 11.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 79 ALA A 99 LYS A 101 MET A 147 LEU A 201 ASP A 212	ATP A 535 ( 3.9A) ATP A 535 (-3.6A) ATP A 535 ( 2.5A) ATP A 535 ( 3.4A) ATP A 535 (-4.8A) MG A 536 (-3.3A)	0.76A	5yu9B-1s9iA: 13.9	5yu9B-1s9iA: 15.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 79 VAL A 86 ALA A 99 LYS A 101 LEU A 201 ASP A 212	ATP A 535 ( 3.9A) ATP A 535 (-4.1A) ATP A 535 (-3.6A) ATP A 535 ( 2.5A) ATP A 535 (-4.8A) MG A 536 (-3.3A)	0.62A	5yu9B-1s9iA: 13.9	5yu9B-1s9iA: 15.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1snx	TYROSINE-PROTEIN KINASE ITK/TSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	GLY A 370 VAL A 377 ALA A 389 LEU A 433 CYH A 442 ASP A 445 LEU A 489	None	0.73A	5yu9B-1snxA: 24.5	5yu9B-1snxA: 16.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1snx	TYROSINE-PROTEIN KINASE ITK/TSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 377 ALA A 389 LEU A 433 CYH A 442 ASP A 445 LEU A 489 ASP A 500	None	0.78A	5yu9B-1snxA: 24.5	5yu9B-1snxA: 16.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1u5q	SERINE/THREONINE PROTEIN KINASE TAO2 (Rattus norvegicus)	PF00069 (Pkinase)	6	GLY A 35 VAL A 42 ALA A 55 LYS A 57 LEU A 103 MET A 105	None	0.83A	5yu9B-1u5qA: 22.3	5yu9B-1u5qA: 13.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1ua2	CELL DIVISION PROTEIN KINASE 7 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 19 VAL A 26 ALA A 39 LYS A 41 LEU A 89 LEU A 144	ATP A 381 ( 3.9A) ATP A 381 (-4.0A) ATP A 381 (-3.6A) ATP A 381 (-2.9A) None None	0.73A	5yu9B-1ua2A: 22.2	5yu9B-1ua2A: 14.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1v0b	CELL DIVISION CONTROL PROTEIN 2 HOMOLOG (Plasmodium falciparum)	PF00069 (Pkinase)	6	GLY A 11 VAL A 18 ALA A 30 LEU A 77 LEU A 132 ASP A 143	None	0.48A	5yu9B-1v0bA: 23.7	5yu9B-1v0bA: 17.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2h8h	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	8	GLY A 274 VAL A 281 ALA A 293 LYS A 295 MET A 314 ASP A 348 LEU A 393 ASP A 404	H8H A 534 ( 3.8A) H8H A 534 (-4.4A) H8H A 534 (-3.2A) H8H A 534 (-3.7A) None None H8H A 534 (-4.5A) H8H A 534 (-4.2A)	0.70A	5yu9B-2h8hA: 32.7	5yu9B-2h8hA: 12.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hck	HEMATOPOETIC CELL KINASE HCK (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	8	GLY A 274 VAL A 281 ALA A 293 LYS A 295 MET A 314 ASP A 348 LEU A 393 ASP A 404	QUE A 1 ( 4.2A) QUE A 1 ( 4.8A) QUE A 1 (-3.5A) None None QUE A 1 ( 4.1A) QUE A 1 (-4.4A) None	0.92A	5yu9B-2hckA: 30.9	5yu9B-2hckA: 11.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2jgz	CELL DIVISION PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 11 VAL A 18 ALA A 31 LYS A 33 LEU A 78 LEU A 134	None	0.69A	5yu9B-2jgzA: 22.2	5yu9B-2jgzA: 19.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ozo	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	8	GLY A 345 VAL A 352 ALA A 367 LYS A 369 MET A 390 LEU A 412 LEU A 468 ASP A 479	ANP A 615 ( 4.4A) ANP A 615 (-4.5A) ANP A 615 (-3.3A) ANP A 615 (-3.1A) None None ANP A 615 (-4.7A) MG A 614 ( 3.2A)	0.78A	5yu9B-2ozoA: 30.9	5yu9B-2ozoA: 8.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ozo	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	8	GLY A 345 VAL A 352 ALA A 367 LYS A 369 MET A 390 MET A 414 LEU A 468 ASP A 479	ANP A 615 ( 4.4A) ANP A 615 (-4.5A) ANP A 615 (-3.3A) ANP A 615 (-3.1A) None ANP A 615 ( 3.9A) ANP A 615 (-4.7A) MG A 614 ( 3.2A)	1.06A	5yu9B-2ozoA: 30.9	5yu9B-2ozoA: 8.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2phk	PHOSPHORYLASE KINASE (Oryctolagus cuniculus)	PF00069 (Pkinase)	7	GLY A 26 VAL A 33 ALA A 46 LEU A 101 ASP A 113 LEU A 156 THR A 166	ATP A 381 (-3.5A) ATP A 381 (-4.1A) ATP A 381 (-3.5A) None None ATP A 381 ( 4.8A) ATP A 381 ( 4.6A)	0.86A	5yu9B-2phkA: 21.9	5yu9B-2phkA: 17.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qkw	PROTEIN KINASE (Solanum pimpinellifolium)	PF07714 (Pkinase_Tyr)	7	GLY B 48 VAL B 55 ALA B 67 LYS B 69 LEU B 112 LEU B 171 THR B 181	None	0.80A	5yu9B-2qkwB: 22.4	5yu9B-2qkwB: 15.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qlu	ACTIVIN RECEPTOR TYPE IIB (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 204 ALA A 215 LYS A 217 LEU A 263 ASP A 275 LEU A 328 ASP A 339	ADE A 488 ( 4.9A) ADE A 488 (-3.2A) None None None ADE A 488 (-4.4A) None	0.93A	5yu9B-2qluA: 23.9	5yu9B-2qluA: 14.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2r4b	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	GLY A 725 VAL A 732 ALA A 749 LYS A 751 LEU A 794 LEU A 850 THR A 860 ASP A 861	None GW7 A 1 ( 4.8A) GW7 A 1 (-3.3A) GW7 A 1 (-3.9A) GW7 A 1 (-4.1A) GW7 A 1 (-4.2A) GW7 A 1 (-3.5A) GW7 A 1 (-4.1A)	0.72A	5yu9B-2r4bA: 37.5	5yu9B-2r4bA: 18.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2r4b	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LYS A 751 MET A 772 LEU A 794 LEU A 850 THR A 860 ASP A 861	GW7 A 1 (-3.9A) GW7 A 1 ( 3.8A) GW7 A 1 (-4.1A) GW7 A 1 (-4.2A) GW7 A 1 (-3.5A) GW7 A 1 (-4.1A)	0.85A	5yu9B-2r4bA: 37.5	5yu9B-2r4bA: 18.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2xk9	CHECKPOINT KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 227 VAL A 234 ALA A 247 ASP A 311 LEU A 354 THR A 367	XK9 A1511 ( 4.5A) XK9 A1511 (-4.8A) XK9 A1511 ( 4.1A) None XK9 A1511 (-4.6A) XK9 A1511 (-3.7A)	0.58A	5yu9B-2xk9A: 21.0	5yu9B-2xk9A: 14.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2y7j	PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS/LIVER ISOFORM (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 31 VAL A 38 ALA A 51 LEU A 105 ASP A 117 LEU A 160	B49 A1294 (-4.0A) None B49 A1294 (-3.2A) None None B49 A1294 (-4.4A)	0.73A	5yu9B-2y7jA: 22.4	5yu9B-2y7jA: 13.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2z7r	RIBOSOMAL PROTEIN S6 KINASE ALPHA-1 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 69 VAL A 76 ALA A 92 LEU A 139 LEU A 194 THR A 204	STU A 1 (-3.3A) None STU A 1 (-3.3A) None STU A 1 (-4.6A) STU A 1 (-3.6A)	0.86A	5yu9B-2z7rA: 22.4	5yu9B-2z7rA: 12.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 202 VAL A 209 ALA A 220 ASP A 276 LEU A 321 ASP A 332	None	0.75A	5yu9B-3d7uA: 24.5	5yu9B-3d7uA: 19.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3dak	SERINE/THREONINE-PRO TEIN KINASE OSR1 (Homo sapiens)	PF00069 (Pkinase)	9	GLY A 24 VAL A 31 ALA A 44 LYS A 46 MET A 67 LEU A 90 ASP A 102 LEU A 153 ASP A 164	ANP A 1 (-3.3A) ANP A 1 (-4.5A) ANP A 1 ( 3.9A) ANP A 1 (-2.8A) None None None None ANP A 1 (-3.8A)	0.98A	5yu9B-3dakA: 22.8	5yu9B-3dakA: 15.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3dtc	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 9 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 151 VAL A 158 ALA A 169 LEU A 218 LEU A 275 THR A 293	VIN A6331 (-3.5A) VIN A6331 (-4.7A) VIN A6331 (-3.4A) None VIN A6331 (-4.5A) VIN A6331 (-3.6A)	0.65A	5yu9B-3dtcA: 21.5	5yu9B-3dtcA: 14.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3dxn	CALMODULIN-LIKE DOMAIN PROTEIN KINASE ISOFORM 3 (Toxoplasma gondii)	PF00069 (Pkinase)	6	GLY A 30 VAL A 37 ALA A 50 LEU A 98 ASP A 110 ASP A 167	None	0.82A	5yu9B-3dxnA: 24.8	5yu9B-3dxnA: 14.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3dxn	CALMODULIN-LIKE DOMAIN PROTEIN KINASE ISOFORM 3 (Toxoplasma gondii)	PF00069 (Pkinase)	6	VAL A 37 ALA A 50 LEU A 98 ASP A 110 LEU A 153 ASP A 167	None	0.73A	5yu9B-3dxnA: 24.8	5yu9B-3dxnA: 14.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3f2a	PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE PIM-1 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 45 VAL A 52 ALA A 65 LEU A 118 ASP A 131 LEU A 174	985 A 1 ( 3.9A) 985 A 1 (-4.5A) 985 A 1 (-3.5A) None None 985 A 1 (-4.8A)	0.85A	5yu9B-3f2aA: 16.1	5yu9B-3f2aA: 14.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3fzp	PROTEIN TYROSINE KINASE 2 BETA (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 432 VAL A 439 ALA A 455 LYS A 457 LEU A 556 ASP A 567	AGS A 999 ( 4.2A) AGS A 999 (-4.6A) AGS A 999 (-3.6A) AGS A 999 (-2.5A) AGS A 999 (-4.5A) AGS A 999 ( 3.9A)	0.85A	5yu9B-3fzpA: 25.1	5yu9B-3fzpA: 18.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3i6u	SERINE/THREONINE-PRO TEIN KINASE CHK2 (Homo sapiens)	PF00069 (Pkinase) PF00498 (FHA)	6	GLY A 227 VAL A 234 ALA A 247 LEU A 354 THR A 367 ASP A 368	None	0.76A	5yu9B-3i6uA: 22.2	5yu9B-3i6uA: 10.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3kex	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	GLY A 697 VAL A 704 LYS A 723 LEU A 766 ASP A 778 LEU A 822 ASP A 833	ANP A 1 (-3.7A) ANP A 1 (-3.9A) ANP A 1 (-3.4A) None None ANP A 1 (-4.7A) MG A1001 ( 3.1A)	0.83A	5yu9B-3kexA: 35.1	5yu9B-3kexA: 15.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3lij	CALCIUM/CALMODULIN DEPENDENT PROTEIN KINASE WITH A KINASE DOMAIN AND 4 CALMODULIN LIKE EF HANDS (Cryptosporidium parvum)	PF00069 (Pkinase) PF13499 (EF-hand_7)	6	GLY A 69 VAL A 76 ALA A 89 LYS A 91 LEU A 136 LEU A 191	ANP A 522 (-3.5A) ANP A 522 (-4.1A) ANP A 522 (-3.6A) ANP A 522 (-3.5A) None ANP A 522 (-4.7A)	0.77A	5yu9B-3lijA: 23.0	5yu9B-3lijA: 9.92
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3lzb	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	11	GLY A 695 VAL A 702 ALA A 719 LYS A 721 MET A 742 LEU A 764 CYH A 773 ASP A 776 LEU A 820 THR A 830 ASP A 831	ITI A 1 ( 4.8A) ITI A 1 (-4.8A) ITI A 1 (-2.9A) ITI A 1 (-2.6A) ITI A 1 (-3.4A) ITI A 1 ( 4.2A) ITI A 1 (-4.8A) None ITI A 1 (-4.6A) ITI A 1 (-3.8A) ITI A 1 ( 4.6A)	0.69A	5yu9B-3lzbA: 38.9	5yu9B-3lzbA: 95.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3niz	RHODANESE FAMILY PROTEIN (Cryptosporidium parvum)	PF00069 (Pkinase)	6	GLY A 30 VAL A 37 ALA A 49 LYS A 51 LEU A 96 LEU A 151	ADP A 314 (-3.3A) ADP A 314 (-4.0A) ADP A 314 (-3.5A) ADP A 314 (-2.8A) None ADP A 314 (-4.6A)	0.89A	5yu9B-3nizA: 22.6	5yu9B-3nizA: 17.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nyo	G PROTEIN-COUPLED RECEPTOR KINASE 6 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	6	GLY A 193 VAL A 200 ALA A 213 LYS A 215 LEU A 261 LEU A 318	AMP A 577 ( 3.7A) AMP A 577 (-4.3A) AMP A 577 (-3.4A) AMP A 577 (-2.8A) None AMP A 577 (-4.8A)	0.81A	5yu9B-3nyoA: 21.1	5yu9B-3nyoA: 9.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3pp0	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	GLY A 727 VAL A 734 ALA A 751 LEU A 796 CYH A 805 ASP A 808 LEU A 852 THR A 862	None 03Q A 1 (-4.5A) 03Q A 1 (-3.1A) 03Q A 1 (-4.3A) None None 03Q A 1 (-4.4A) 03Q A 1 (-3.3A)	0.64A	5yu9B-3pp0A: 34.9	5yu9B-3pp0A: 59.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3pp0	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	GLY A 727 VAL A 734 ALA A 751 MET A 774 CYH A 805 ASP A 808 THR A 862	None 03Q A 1 (-4.5A) 03Q A 1 (-3.1A) 03Q A 1 (-4.5A) None None 03Q A 1 (-3.3A)	1.37A	5yu9B-3pp0A: 34.9	5yu9B-3pp0A: 59.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3pp0	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 734 ALA A 751 LEU A 796 CYH A 805 ASP A 808 LEU A 852 ASP A 863	03Q A 1 (-4.5A) 03Q A 1 (-3.1A) 03Q A 1 (-4.3A) None None 03Q A 1 (-4.4A) 03Q A 1 (-4.0A)	0.85A	5yu9B-3pp0A: 34.9	5yu9B-3pp0A: 59.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3sxf	CALMODULIN-DOMAIN PROTEIN KINASE 1 (Toxoplasma gondii)	PF00069 (Pkinase) PF13499 (EF-hand_7)	7	GLY A 58 VAL A 65 ALA A 78 LYS A 80 LEU A 126 LEU A 181 ASP A 195	BK5 A 701 ( 3.8A) BK5 A 701 (-4.2A) BK5 A 701 (-3.4A) BK5 A 701 (-3.5A) BK5 A 701 (-3.3A) None BK5 A 701 (-4.0A)	0.70A	5yu9B-3sxfA: 23.6	5yu9B-3sxfA: 11.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3sxs	CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 424 VAL A 431 ALA A 443 LYS A 445 CYH A 496 LEU A 543	PP2 A 1 ( 4.1A) PP2 A 1 (-4.5A) PP2 A 1 (-3.2A) PP2 A 1 (-4.5A) None PP2 A 1 (-4.6A)	0.81A	5yu9B-3sxsA: 23.6	5yu9B-3sxsA: 18.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3ulz	BRASSINOSTEROID INSENSITIVE 1-ASSOCIATED RECEPTOR KINASE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	7	GLY A 296 VAL A 303 ALA A 315 LYS A 317 LEU A 361 LEU A 423 ASP A 434	None	0.94A	5yu9B-3ulzA: 21.5	5yu9B-3ulzA: 15.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 60 VAL A 67 ALA A 80 MET A 129 LEU A 186 ASP A 197	ANK A 401 (-3.4A) ANK A 401 (-4.3A) ANK A 401 (-3.0A) ANK A 401 (-3.7A) ANK A 401 ( 4.9A) MG A 402 ( 2.8A)	0.80A	5yu9B-3vn9A: 24.0	5yu9B-3vn9A: 12.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	GLY A 76 VAL A 83 ALA A 96 LYS A 98 MET A 144 ASP A 153 LEU A 198	ANP A 401 ( 3.7A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) ANP A 401 (-2.7A) CHU A 403 (-3.8A) None ANP A 401 (-4.8A)	1.27A	5yu9B-3wigA: 23.3	5yu9B-3wigA: 16.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	GLY A 76 VAL A 83 ALA A 96 LYS A 98 MET A 144 LEU A 198 ASP A 209	ANP A 401 ( 3.7A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) ANP A 401 (-2.7A) CHU A 403 (-3.8A) ANP A 401 (-4.8A) MG A 402 (-3.2A)	0.81A	5yu9B-3wigA: 23.3	5yu9B-3wigA: 16.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 11 VAL A 18 ALA A 31 LYS A 33 LEU A 78 LEU A 133	D15 A 500 (-3.8A) D15 A 500 (-4.6A) D15 A 500 (-3.4A) D15 A 500 ( 4.1A) None D15 A 500 (-4.5A)	0.65A	5yu9B-4aguA: 22.4	5yu9B-4aguA: 13.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4c02	ACTIVIN RECEPTOR TYPE-1 (Homo sapiens)	PF00069 (Pkinase) PF08515 (TGF_beta_GS)	8	GLY A 215 VAL A 222 ALA A 233 LYS A 235 LEU A 281 ASP A 293 LEU A 343 ASP A 354	None TAK A1507 (-4.7A) TAK A1507 (-3.3A) TAK A1507 ( 4.5A) None None TAK A1507 (-4.7A) TAK A1507 (-3.5A)	0.87A	5yu9B-4c02A: 25.0	5yu9B-4c02A: 15.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4c0t	LIKELY PROTEIN KINASE (Candida albicans)	PF00069 (Pkinase)	6	GLY A 247 VAL A 254 ALA A 267 LEU A 371 THR A 381 ASP A 382	None	0.81A	5yu9B-4c0tA: 20.6	5yu9B-4c0tA: 7.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4eqm	PROTEIN KINASE (Staphylococcus aureus)	PF00069 (Pkinase)	6	GLY A 17 VAL A 24 ALA A 37 LYS A 39 LEU A 85 ASP A 151	ANP A 300 ( 4.4A) ANP A 300 ( 4.7A) ANP A 300 ( 3.8A) ANP A 300 (-3.1A) None None	0.72A	5yu9B-4eqmA: 23.4	5yu9B-4eqmA: 14.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4f4p	TYROSINE-PROTEIN KINASE SYK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	GLY A 378 VAL A 385 ALA A 400 LYS A 402 LEU A 446 LEU A 501 ASP A 512	0SB A 701 (-3.6A) 0SB A 701 (-4.0A) 0SB A 701 (-3.3A) 0SB A 701 ( 4.8A) None 0SB A 701 (-4.4A) 0SB A 701 (-3.9A)	0.97A	5yu9B-4f4pA: 25.5	5yu9B-4f4pA: 45.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fie	SERINE/THREONINE-PRO TEIN KINASE PAK 4 (Homo sapiens)	PF00069 (Pkinase) PF00786 (PBD)	6	GLY A 328 VAL A 335 ALA A 348 LYS A 350 LEU A 447 ASP A 458	ANP A1001 (-4.4A) ANP A1001 (-4.7A) ANP A1001 (-3.6A) ANP A1001 (-3.0A) ANP A1001 (-4.7A) ANP A1001 (-2.7A)	0.84A	5yu9B-4fieA: 21.8	5yu9B-4fieA: 11.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fl3	TYROSINE-PROTEIN KINASE SYK (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	8	GLY A 378 VAL A 385 ALA A 400 LYS A 402 MET A 424 LEU A 446 LEU A 501 ASP A 512	ANP A 701 ( 4.0A) ANP A 701 (-4.1A) ANP A 701 (-3.3A) ANP A 701 (-2.7A) None None ANP A 701 (-4.5A) MG A 702 ( 3.1A)	0.59A	5yu9B-4fl3A: 24.8	5yu9B-4fl3A: 7.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fl3	TYROSINE-PROTEIN KINASE SYK (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	7	GLY A 378 VAL A 385 ALA A 400 LYS A 402 MET A 448 LEU A 501 ASP A 512	ANP A 701 ( 4.0A) ANP A 701 (-4.1A) ANP A 701 (-3.3A) ANP A 701 (-2.7A) ANP A 701 ( 3.7A) ANP A 701 (-4.5A) MG A 702 ( 3.1A)	0.84A	5yu9B-4fl3A: 24.8	5yu9B-4fl3A: 7.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4gl9	TYROSINE-PROTEIN KINASE (Mus musculus)	PF07714 (Pkinase_Tyr)	6	GLY A 856 VAL A 863 ALA A 880 LEU A 927 ASP A 939 LEU A 983	IZA A2001 ( 4.9A) None IZA A2001 (-3.4A) None None IZA A2001 ( 4.7A)	0.89A	5yu9B-4gl9A: 28.2	5yu9B-4gl9A: 15.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14604 (SH3_9)	8	GLY A 133 VAL A 140 ALA A 156 LYS A 158 MET A 181 ASP A 215 LEU A 259 ASP A 270	None	0.76A	5yu9B-4hzsA: 31.3	5yu9B-4hzsA: 13.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4id7	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	GLY A 133 VAL A 140 ALA A 156 LYS A 158 MET A 181 ASP A 215 LEU A 259	1G0 A 401 ( 4.2A) 1G0 A 401 (-4.4A) 1G0 A 401 (-3.6A) 1G0 A 401 (-3.7A) 1G0 A 401 (-4.0A) None 1G0 A 401 (-4.6A)	1.39A	5yu9B-4id7A: 29.7	5yu9B-4id7A: 15.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4jrn	RHOPTRY KINASE FAMILY PROTEIN (Toxoplasma gondii)	PF14531 (Kinase-like)	7	GLY A 259 VAL A 266 ALA A 279 LYS A 281 LEU A 354 MET A 356 LEU A 416	ANP A 601 (-3.4A) ANP A 601 (-4.1A) ANP A 601 ( 3.9A) ANP A 601 (-3.2A) None ANP A 601 (-3.3A) ANP A 601 ( 4.9A)	0.96A	5yu9B-4jrnA: 18.8	5yu9B-4jrnA: 13.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4k11	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	8	GLY A 274 VAL A 281 ALA A 293 LYS A 295 MET A 314 ASP A 348 LEU A 393 ASP A 404	0J9 A 601 ( 4.0A) 0J9 A 601 (-4.4A) 0J9 A 601 (-3.3A) 0J9 A 601 ( 4.7A) None None 0J9 A 601 (-4.5A) 0J9 A 601 (-3.1A)	0.61A	5yu9B-4k11A: 32.7	5yu9B-4k11A: 15.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ks8	SERINE/THREONINE-PRO TEIN KINASE PAK 6 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 414 VAL A 421 ALA A 434 ASP A 491 LEU A 533 ASP A 544	B49 A 701 ( 4.3A) None B49 A 701 (-3.2A) B49 A 701 ( 4.3A) B49 A 701 (-4.5A) B49 A 701 (-4.6A)	0.72A	5yu9B-4ks8A: 23.2	5yu9B-4ks8A: 14.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4lgg	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Gallus gallus)	PF07714 (Pkinase_Tyr)	7	GLY A 274 VAL A 281 ALA A 293 LYS A 295 ASP A 348 LEU A 393 ASP A 404	VGG A 601 ( 3.8A) VGG A 601 ( 3.5A) VGG A 601 (-3.5A) VGG A 601 (-3.8A) None VGG A 601 (-4.5A) VGG A 601 ( 4.7A)	0.85A	5yu9B-4lggA: 28.4	5yu9B-4lggA: 18.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4m69	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 3 (Mus musculus)	PF00069 (Pkinase)	7	GLY A 29 VAL A 36 ALA A 49 LYS A 51 LEU A 93 LEU A 150 ASP A 161	ANP A 401 (-3.8A) ANP A 401 (-4.5A) ANP A 401 (-3.1A) ANP A 401 (-2.9A) None ANP A 401 (-4.8A) MG A 403 ( 3.1A)	0.76A	5yu9B-4m69A: 26.5	5yu9B-4m69A: 14.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4m69	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 3 (Mus musculus)	PF00069 (Pkinase)	7	GLY A 29 VAL A 36 ALA A 49 LYS A 51 MET A 65 LEU A 93 LEU A 150	ANP A 401 (-3.8A) ANP A 401 (-4.5A) ANP A 401 (-3.1A) ANP A 401 (-2.9A) None None ANP A 401 (-4.8A)	1.00A	5yu9B-4m69A: 26.5	5yu9B-4m69A: 14.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ow8	SERINE/THREONINE-PRO TEIN KINASE PKNA (Mycobacterium tuberculosis)	PF00069 (Pkinase)	6	VAL A 27 ALA A 40 LYS A 42 LEU A 93 THR A 158 ASP A 159	None	0.83A	5yu9B-4ow8A: 23.7	5yu9B-4ow8A: 15.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4rgj	CALCIUM-DEPENDENT PROTEIN KINASE 4 (Plasmodium falciparum)	PF00069 (Pkinase) PF13499 (EF-hand_7)	6	GLY A 77 VAL A 84 ALA A 97 LYS A 99 LEU A 145 ASP A 215	None	0.39A	5yu9B-4rgjA: 23.2	5yu9B-4rgjA: 10.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4tnb	G PROTEIN-COUPLED RECEPTOR KINASE 5 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	6	GLY A 193 VAL A 200 ALA A 213 LEU A 261 LEU A 318 ASP A 329	SGV A 601 (-3.4A) SGV A 601 ( 4.6A) SGV A 601 (-3.3A) None SGV A 601 (-4.9A) SGV A 601 (-3.0A)	0.74A	5yu9B-4tnbA: 19.7	5yu9B-4tnbA: 9.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4uya	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLK4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 131 VAL A 138 ALA A 149 LEU A 198 LEU A 270 THR A 288	AGS A1438 ( 3.8A) AGS A1438 (-4.4A) AGS A1438 (-3.4A) None AGS A1438 (-4.7A) AGS A1438 ( 4.7A)	0.75A	5yu9B-4uyaA: 26.0	5yu9B-4uyaA: 16.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	GLY A 409 VAL A 416 ALA A 428 MET A 449 CYH A 481 LEU A 528 ASP A 539	None	0.88A	5yu9B-4xi2A: 26.7	5yu9B-4xi2A: 11.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4y93	NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE (Bos taurus)	PF00169 (PH) PF00779 (BTK) PF07714 (Pkinase_Tyr)	6	GLY A 409 VAL A 416 ALA A 428 CYH A 481 LEU A 528 ASP A 539	746 A 702 ( 3.5A) 746 A 702 ( 4.3A) 746 A 702 (-2.4A) None 746 A 702 (-4.4A) 746 A 702 (-3.7A)	0.65A	5yu9B-4y93A: 30.7	5yu9B-4y93A: 10.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4y93	NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE (Bos taurus)	PF00169 (PH) PF00779 (BTK) PF07714 (Pkinase_Tyr)	6	VAL A 416 ALA A 428 MET A 449 CYH A 481 LEU A 528 ASP A 539	746 A 702 ( 4.3A) 746 A 702 (-2.4A) None None 746 A 702 (-4.4A) 746 A 702 (-3.7A)	0.86A	5yu9B-4y93A: 30.7	5yu9B-4y93A: 10.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4yc6	CYCLIN-DEPENDENT KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	GLY A 11 VAL A 18 ALA A 31 LYS A 33 LEU A 78 LEU A 135 ASP A 146	None	0.68A	5yu9B-4yc6A: 23.8	5yu9B-4yc6A: 16.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4yhj	G PROTEIN-COUPLED RECEPTOR KINASE 4 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	6	GLY A 194 VAL A 201 ALA A 214 LYS A 216 LEU A 262 LEU A 319	AN2 A 601 (-3.4A) AN2 A 601 (-4.0A) AN2 A 601 (-3.6A) AN2 A 601 ( 3.9A) None None	0.85A	5yu9B-4yhjA: 19.7	5yu9B-4yhjA: 9.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ynz	SERINE/THREONINE-PRO TEIN KINASE BRSK2 (Mus musculus)	PF00069 (Pkinase)	7	GLY A 27 VAL A 34 ALA A 47 LYS A 49 LEU A 94 LEU A 149 ASP A 160	None	0.71A	5yu9B-4ynzA: 21.3	5yu9B-4ynzA: 12.87
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5dbx	STE20/SPS1-RELATED PROLINE-ALANINE-RICH PROTEIN KINASE (Mus musculus)	PF00069 (Pkinase)	7	GLY A 82 VAL A 89 ALA A 102 LYS A 104 LEU A 148 ASP A 160 LEU A 211	ANP A 401 ( 3.9A) ANP A 401 (-4.0A) ANP A 401 ( 4.0A) ANP A 401 (-3.0A) None None None	0.95A	5yu9B-5dbxA: 22.2	5yu9B-5dbxA: 14.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5e8y	TGF-BETA RECEPTOR TYPE-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 251 VAL A 258 ALA A 275 LYS A 277 LEU A 323 LEU A 386	STU A 601 (-2.9A) STU A 601 (-4.0A) STU A 601 (-3.1A) STU A 601 (-2.4A) None STU A 601 (-3.9A)	0.68A	5yu9B-5e8yA: 18.6	5yu9B-5e8yA: 13.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5eyk	AURORA KINASE B-A (Xenopus laevis)	PF00069 (Pkinase)	6	GLY A 100 VAL A 107 ALA A 120 LYS A 122 LEU A 168 LEU A 223	5U5 A 401 (-3.8A) 5U5 A 401 ( 4.3A) 5U5 A 401 (-3.5A) 5U5 A 401 (-2.6A) None 5U5 A 401 (-4.7A)	0.72A	5yu9B-5eykA: 22.3	5yu9B-5eykA: 15.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5fm2	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 731 VAL A 738 ALA A 756 LYS A 758 LEU A 802 LEU A 881	PP1 A2012 ( 3.9A) PP1 A2012 (-4.4A) PP1 A2012 (-3.2A) PP1 A2012 (-4.1A) None PP1 A2012 (-4.6A)	0.52A	5yu9B-5fm2A: 29.0	5yu9B-5fm2A: 14.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ig1	CAMK/CAMK2 PROTEIN KINASE (Salpingoeca rosetta)	PF00069 (Pkinase)	6	GLY A 25 VAL A 32 ALA A 45 LYS A 47 LEU A 92 THR A 160	None	0.87A	5yu9B-5ig1A: 22.8	5yu9B-5ig1A: 12.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j9z	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	GLY A 719 VAL A 726 ALA A 743 LEU A 788 MET A 790 CYH A 797 ASP A 800 LEU A 844 THR A 854	6HJ A1101 ( 4.2A) 6HJ A1101 ( 4.7A) 6HJ A1101 (-3.1A) 6HJ A1101 ( 4.6A) 6HJ A1101 (-3.4A) 6HJ A1101 (-1.6A) 6HJ A1101 ( 4.1A) 6HJ A1101 ( 4.8A) 6HJ A1101 (-3.9A)	0.58A	5yu9B-5j9zA: 35.8	5yu9B-5j9zA: 95.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j9z	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	GLY A 719 VAL A 726 ALA A 743 LYS A 745 LEU A 788 MET A 790 LEU A 844	6HJ A1101 ( 4.2A) 6HJ A1101 ( 4.7A) 6HJ A1101 (-3.1A) 6HJ A1101 (-4.2A) 6HJ A1101 ( 4.6A) 6HJ A1101 (-3.4A) 6HJ A1101 ( 4.8A)	0.66A	5yu9B-5j9zA: 35.8	5yu9B-5j9zA: 95.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j9z	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	GLY A 719 VAL A 726 ALA A 743 MET A 790 CYH A 797 ASP A 800 LEU A 844 THR A 854 ASP A 855	6HJ A1101 ( 4.2A) 6HJ A1101 ( 4.7A) 6HJ A1101 (-3.1A) 6HJ A1101 (-3.4A) 6HJ A1101 (-1.6A) 6HJ A1101 ( 4.1A) 6HJ A1101 ( 4.8A) 6HJ A1101 (-3.9A) 6HJ A1101 (-4.3A)	0.74A	5yu9B-5j9zA: 35.8	5yu9B-5j9zA: 95.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5jzn	SERINE/THREONINE-PRO TEIN KINASE DCLK1 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 397 VAL A 404 ALA A 417 LEU A 463 ASP A 475 LEU A 518	GUI A 701 ( 3.8A) GUI A 701 (-4.4A) GUI A 701 ( 3.9A) None GUI A 701 (-4.1A) GUI A 701 (-4.4A)	0.61A	5yu9B-5jznA: 22.4	5yu9B-5jznA: 16.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5kbr	SERINE/THREONINE-PRO TEIN KINASE PAK 1 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 277 VAL A 284 ALA A 297 ASP A 354 LEU A 396 THR A 406	IPW A 601 ( 3.9A) IPW A 601 (-4.2A) IPW A 601 (-3.5A) None IPW A 601 (-4.5A) IPW A 601 (-3.7A)	0.70A	5yu9B-5kbrA: 21.7	5yu9B-5kbrA: 17.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5kbr	SERINE/THREONINE-PRO TEIN KINASE PAK 1 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 277 VAL A 284 ALA A 297 LYS A 299 LEU A 396 THR A 406	IPW A 601 ( 3.9A) IPW A 601 (-4.2A) IPW A 601 (-3.5A) IPW A 601 (-4.5A) IPW A 601 (-4.5A) IPW A 601 (-3.7A)	0.61A	5yu9B-5kbrA: 21.7	5yu9B-5kbrA: 17.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5lpy	PROTEIN BRASSINOSTEROID INSENSITIVE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	7	GLY A 890 VAL A 897 ALA A 909 LYS A 911 LEU A 954 LEU A1016 ASP A1027	ATP A1200 ( 4.6A) ATP A1200 ( 4.5A) ATP A1200 (-3.5A) ATP A1200 (-3.8A) None ATP A1200 (-4.6A) ATP A1200 (-4.1A)	0.90A	5yu9B-5lpyA: 22.0	5yu9B-5lpyA: 16.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5lpy	PROTEIN BRASSINOSTEROID INSENSITIVE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	7	GLY A 890 VAL A 897 LYS A 911 LEU A 954 ASP A 966 LEU A1016 ASP A1027	ATP A1200 ( 4.6A) ATP A1200 ( 4.5A) ATP A1200 (-3.8A) None ATP A1200 (-3.9A) ATP A1200 (-4.6A) ATP A1200 (-4.1A)	1.04A	5yu9B-5lpyA: 22.0	5yu9B-5lpyA: 16.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5lpz	PROTEIN BRASSINOSTEROID INSENSITIVE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	8	GLY A 890 VAL A 897 ALA A 909 LYS A 911 LEU A 954 ASP A 966 LEU A1016 ASP A1027	ADP A1200 ( 4.0A) ADP A1200 (-4.4A) ADP A1200 (-3.5A) ADP A1200 ( 4.3A) None ADP A1200 (-4.2A) ADP A1200 (-4.7A) ADP A1200 (-3.4A)	1.03A	5yu9B-5lpzA: 22.2	5yu9B-5lpzA: 13.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5m09	SERINE/THREONINE-PRO TEIN KINASE PKNI (Mycobacterium tuberculosis)	PF00069 (Pkinase)	6	GLY A 19 VAL A 26 ALA A 39 LYS A 41 MET A 89 ASP A 159	None	0.78A	5yu9B-5m09A: 21.3	5yu9B-5m09A: 13.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ncl	SERINE/THREONINE-PRO TEIN KINASE CBK1 (Saccharomyces cerevisiae)	no annotation	6	GLY A 359 VAL A 366 ALA A 379 LYS A 381 LEU A 427 LEU A 482	ANP A 801 ( 4.1A) ANP A 801 (-4.7A) ANP A 801 ( 3.9A) ANP A 801 (-2.6A) None ANP A 801 (-4.8A)	0.68A	5yu9B-5nclA: 19.0	5yu9B-5nclA: 21.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5tur	SERINE/THREONINE-PRO TEIN KINASE PIM-1 (Homo sapiens)	no annotation	6	GLY A 45 VAL A 52 ALA A 65 LEU A 118 ASP A 131 LEU A 174	None 7LK A 401 (-4.9A) 7LK A 401 (-3.3A) None 7LK A 401 (-3.0A) 7LK A 401 (-4.8A)	0.84A	5yu9B-5turA: 21.9	5yu9B-5turA: 11.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5vef	SERINE/THREONINE-PRO TEIN KINASE PAK 4 (Homo sapiens)	no annotation	7	GLY A 328 VAL A 335 ALA A 348 LYS A 350 MET A 395 LEU A 447 ASP A 458	M77 A 601 (-3.4A) M77 A 601 (-4.5A) M77 A 601 ( 3.5A) M77 A 601 ( 4.7A) M77 A 601 ( 2.9A) M77 A 601 (-4.6A) M77 A 601 ( 3.5A)	1.20A	5yu9B-5vefA: 22.7	5yu9B-5vefA: 13.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5wno	RECEPTOR TYROSINE-PROTEIN KINASE LET-23 (Caenorhabditis elegans)	no annotation	7	GLY A 892 VAL A 899 ALA A 917 LYS A 919 MET A 938 THR A1027 ASP A1028	ANP A1201 ( 3.8A) ANP A1201 (-4.4A) ANP A1201 (-3.3A) ANP A1201 (-3.8A) None ANP A1201 ( 4.9A) MG A1202 ( 3.0A)	0.94A	5yu9B-5wnoA: 34.6	5yu9B-5wnoA: 42.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5wno	RECEPTOR TYROSINE-PROTEIN KINASE LET-23 (Caenorhabditis elegans)	no annotation	7	GLY A 892 VAL A 899 ALA A 917 MET A 938 LEU A1017 THR A1027 ASP A1028	ANP A1201 ( 3.8A) ANP A1201 (-4.4A) ANP A1201 (-3.3A) None ANP A1201 (-4.7A) ANP A1201 ( 4.9A) MG A1202 ( 3.0A)	0.77A	5yu9B-5wnoA: 34.6	5yu9B-5wnoA: 42.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5xd6	PROTEIN KINASE SUPERFAMILY PROTEIN (Arabidopsis thaliana)	no annotation	6	GLY A 76 VAL A 83 ALA A 95 LYS A 97 LEU A 139 LEU A 206	ANP A1000 ( 3.8A) ANP A1000 (-4.1A) ANP A1000 (-3.2A) ANP A1000 (-2.8A) None ANP A1000 (-4.5A)	0.70A	5yu9B-5xd6A: 23.9	5yu9B-5xd6A: 29.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5xd6	PROTEIN KINASE SUPERFAMILY PROTEIN (Arabidopsis thaliana)	no annotation	6	GLY A 76 VAL A 83 LYS A 97 LEU A 139 ASP A 151 LEU A 206	ANP A1000 ( 3.8A) ANP A1000 (-4.1A) ANP A1000 (-2.8A) None ANP A1000 ( 4.9A) ANP A1000 (-4.5A)	0.59A	5yu9B-5xd6A: 23.9	5yu9B-5xd6A: 29.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5xzw	SERINE/THREONINE-PRO TEIN KINASE RAD53 (Saccharomyces cerevisiae)	no annotation	6	GLY A 205 VAL A 212 ALA A 225 LEU A 326 THR A 338 ASP A 339	None	0.75A	5yu9B-5xzwA: 18.7	5yu9B-5xzwA: 10.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6ao5	SERINE/THREONINE-PRO TEIN KINASE 3 (Homo sapiens)	no annotation	6	GLY A 34 VAL A 41 ALA A 54 LYS A 56 MET A 74 ASP A 164	ANP A 501 ( 3.9A) ANP A 501 (-4.4A) ANP A 501 ( 3.7A) ANP A 501 (-2.4A) None MG A 502 ( 3.1A)	0.87A	5yu9B-6ao5A: 23.4	5yu9B-6ao5A: 13.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6ao5	SERINE/THREONINE-PRO TEIN KINASE 3 (Homo sapiens)	no annotation	7	GLY A 34 VAL A 41 ALA A 54 LYS A 56 MET A 99 LEU A 153 ASP A 164	ANP A 501 ( 3.9A) ANP A 501 (-4.4A) ANP A 501 ( 3.7A) ANP A 501 (-2.4A) ANP A 501 (-2.5A) ANP A 501 (-4.6A) MG A 502 ( 3.1A)	0.75A	5yu9B-6ao5A: 23.4	5yu9B-6ao5A: 13.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6bfn	INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 1 (Homo sapiens)	no annotation	6	GLY A 219 VAL A 226 ALA A 237 LEU A 286 LEU A 347 ASP A 358	DL1 A 601 ( 4.1A) None DL1 A 601 (-3.4A) None DL1 A 601 (-3.9A) DL1 A 601 (-3.1A)	0.60A	5yu9B-6bfnA: 22.9	5yu9B-6bfnA: 29.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6eqi	SERINE/THREONINE-PRO TEIN KINASE PINK1, PUTATIVE (Pediculus humanus)	no annotation	6	VAL C 173 ALA C 191 LEU C 288 LEU C 341 THR C 356 ASP C 357	None	0.60A	5yu9B-6eqiC: 20.4	5yu9B-6eqiC: 12.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6f3d	INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 (Homo sapiens)	no annotation	6	GLY A 193 VAL A 200 ALA A 211 LEU A 260 ASP A 272 LEU A 318	CJT A 502 ( 3.9A) CJT A 502 ( 4.8A) CJT A 502 (-3.4A) None CJT A 502 (-3.3A) CJT A 502 (-4.7A)	0.60A	5yu9B-6f3dA: 22.4	5yu9B-6f3dA: 26.14

[["5YU9_B_1E8B1101_1","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"GLY A 202;VAL A 209;ALA A 220;ASP A 276;LEU A 321;ASP A 332","None","0.75A","5yu9B-1k9aA:30.1","5yu9B-1k9aA:12.83"],["5YU9_B_1E8B1101_1","1py5","Homo sapiens","TGF-BETA RECEPTOR TYPE I","PF00069(Pkinase);PF08515(TGF_beta_GS)",7,"GLY A 212;VAL A 219;ALA A 230;LEU A 278;ASP A 290;LEU A 340;ASP A 351","None;PY1 A 700 ( 4.7A);PY1 A 700 (-3.5A);PY1 A 700 (-3.8A);None;PY1 A 700 (-4.4A);PY1 A 700 (-2.7A)","0.82A","5yu9B-1py5A:24.6","5yu9B-1py5A:11.15"],["5YU9_B_1E8B1101_1","1py5","Homo sapiens","TGF-BETA RECEPTOR TYPE I","PF00069(Pkinase);PF08515(TGF_beta_GS)",7,"GLY A 212;VAL A 219;ALA A 230;LYS A 232;ASP A 290;LEU A 340;ASP A 351","None;PY1 A 700 ( 4.7A);PY1 A 700 (-3.5A);PY1 A 700 (-3.9A);None;PY1 A 700 (-4.4A);PY1 A 700 (-2.7A)","0.97A","5yu9B-1py5A:24.6","5yu9B-1py5A:11.15"],["5YU9_B_1E8B1101_1","1s9i","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","PF00069(Pkinase)",6,"GLY A  79;ALA A  99;LYS A 101;MET A 147;LEU A 201;ASP A 212","ATP A 535 ( 3.9A);ATP A 535 (-3.6A);ATP A 535 ( 2.5A);ATP A 535 ( 3.4A);ATP A 535 (-4.8A); MG A 536 (-3.3A)","0.76A","5yu9B-1s9iA:13.9","5yu9B-1s9iA:15.71"],["5YU9_B_1E8B1101_1","1s9i","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","PF00069(Pkinase)",6,"GLY A  79;VAL A  86;ALA A  99;LYS A 101;LEU A 201;ASP A 212","ATP A 535 ( 3.9A);ATP A 535 (-4.1A);ATP A 535 (-3.6A);ATP A 535 ( 2.5A);ATP A 535 (-4.8A); MG A 536 (-3.3A)","0.62A","5yu9B-1s9iA:13.9","5yu9B-1s9iA:15.71"],["5YU9_B_1E8B1101_1","1snx","Homo sapiens","TYROSINE-PROTEIN KINASE ITK\/TSK","PF07714(Pkinase_Tyr)",7,"GLY A 370;VAL A 377;ALA A 389;LEU A 433;CYH A 442;ASP A 445;LEU A 489","None","0.73A","5yu9B-1snxA:24.5","5yu9B-1snxA:16.00"],["5YU9_B_1E8B1101_1","1snx","Homo sapiens","TYROSINE-PROTEIN KINASE ITK\/TSK","PF07714(Pkinase_Tyr)",7,"VAL A 377;ALA A 389;LEU A 433;CYH A 442;ASP A 445;LEU A 489;ASP A 500","None","0.78A","5yu9B-1snxA:24.5","5yu9B-1snxA:16.00"],["5YU9_B_1E8B1101_1","1u5q","Rattus norvegicus","SERINE\/THREONINE PROTEIN KINASE TAO2","PF00069(Pkinase)",6,"GLY A  35;VAL A  42;ALA A  55;LYS A  57;LEU A 103;MET A 105","None","0.83A","5yu9B-1u5qA:22.3","5yu9B-1u5qA:13.18"],["5YU9_B_1E8B1101_1","1ua2","Homo sapiens","CELL DIVISION PROTEIN KINASE 7","PF00069(Pkinase)",6,"GLY A  19;VAL A  26;ALA A  39;LYS A  41;LEU A  89;LEU A 144","ATP A 381 ( 3.9A);ATP A 381 (-4.0A);ATP A 381 (-3.6A);ATP A 381 (-2.9A);None;None","0.73A","5yu9B-1ua2A:22.2","5yu9B-1ua2A:14.64"],["5YU9_B_1E8B1101_1","1v0b","Plasmodium falciparum","CELL DIVISION CONTROL PROTEIN 2 HOMOLOG","PF00069(Pkinase)",6,"GLY A  11;VAL A  18;ALA A  30;LEU A  77;LEU A 132;ASP A 143","None","0.48A","5yu9B-1v0bA:23.7","5yu9B-1v0bA:17.01"],["5YU9_B_1E8B1101_1","2h8h","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",8,"GLY A 274;VAL A 281;ALA A 293;LYS A 295;MET A 314;ASP A 348;LEU A 393;ASP A 404","H8H A 534 ( 3.8A);H8H A 534 (-4.4A);H8H A 534 (-3.2A);H8H A 534 (-3.7A);None;None;H8H A 534 (-4.5A);H8H A 534 (-4.2A)","0.70A","5yu9B-2h8hA:32.7","5yu9B-2h8hA:12.89"],["5YU9_B_1E8B1101_1","2hck","Homo sapiens","HEMATOPOETIC CELL KINASE HCK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",8,"GLY A 274;VAL A 281;ALA A 293;LYS A 295;MET A 314;ASP A 348;LEU A 393;ASP A 404","QUE A   1 ( 4.2A);QUE A   1 ( 4.8A);QUE A   1 (-3.5A);None;None;QUE A   1 ( 4.1A);QUE A   1 (-4.4A);None","0.92A","5yu9B-2hckA:30.9","5yu9B-2hckA:11.29"],["5YU9_B_1E8B1101_1","2jgz","Homo sapiens","CELL DIVISION PROTEIN KINASE 2","PF00069(Pkinase)",6,"GLY A  11;VAL A  18;ALA A  31;LYS A  33;LEU A  78;LEU A 134","None","0.69A","5yu9B-2jgzA:22.2","5yu9B-2jgzA:19.23"],["5YU9_B_1E8B1101_1","2ozo","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF00017(SH2);PF07714(Pkinase_Tyr)",8,"GLY A 345;VAL A 352;ALA A 367;LYS A 369;MET A 390;LEU A 412;LEU A 468;ASP A 479","ANP A 615 ( 4.4A);ANP A 615 (-4.5A);ANP A 615 (-3.3A);ANP A 615 (-3.1A);None;None;ANP A 615 (-4.7A); MG A 614 ( 3.2A)","0.78A","5yu9B-2ozoA:30.9","5yu9B-2ozoA:8.25"],["5YU9_B_1E8B1101_1","2ozo","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF00017(SH2);PF07714(Pkinase_Tyr)",8,"GLY A 345;VAL A 352;ALA A 367;LYS A 369;MET A 390;MET A 414;LEU A 468;ASP A 479","ANP A 615 ( 4.4A);ANP A 615 (-4.5A);ANP A 615 (-3.3A);ANP A 615 (-3.1A);None;ANP A 615 ( 3.9A);ANP A 615 (-4.7A); MG A 614 ( 3.2A)","1.06A","5yu9B-2ozoA:30.9","5yu9B-2ozoA:8.25"],["5YU9_B_1E8B1101_1","2phk","Oryctolagus cuniculus","PHOSPHORYLASE KINASE","PF00069(Pkinase)",7,"GLY A  26;VAL A  33;ALA A  46;LEU A 101;ASP A 113;LEU A 156;THR A 166","ATP A 381 (-3.5A);ATP A 381 (-4.1A);ATP A 381 (-3.5A);None;None;ATP A 381 ( 4.8A);ATP A 381 ( 4.6A)","0.86A","5yu9B-2phkA:21.9","5yu9B-2phkA:17.20"],["5YU9_B_1E8B1101_1","2qkw","Solanum pimpinellifolium","PROTEIN KINASE","PF07714(Pkinase_Tyr)",7,"GLY B  48;VAL B  55;ALA B  67;LYS B  69;LEU B 112;LEU B 171;THR B 181","None","0.80A","5yu9B-2qkwB:22.4","5yu9B-2qkwB:15.38"],["5YU9_B_1E8B1101_1","2qlu","Homo sapiens","ACTIVIN RECEPTOR TYPE IIB","PF00069(Pkinase)",7,"VAL A 204;ALA A 215;LYS A 217;LEU A 263;ASP A 275;LEU A 328;ASP A 339","ADE A 488 ( 4.9A);ADE A 488 (-3.2A);None;None;None;ADE A 488 (-4.4A);None","0.93A","5yu9B-2qluA:23.9","5yu9B-2qluA:14.33"],["5YU9_B_1E8B1101_1","2r4b","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","PF07714(Pkinase_Tyr)",8,"GLY A 725;VAL A 732;ALA A 749;LYS A 751;LEU A 794;LEU A 850;THR A 860;ASP A 861","None;GW7 A   1 ( 4.8A);GW7 A   1 (-3.3A);GW7 A   1 (-3.9A);GW7 A   1 (-4.1A);GW7 A   1 (-4.2A);GW7 A   1 (-3.5A);GW7 A   1 (-4.1A)","0.72A","5yu9B-2r4bA:37.5","5yu9B-2r4bA:18.38"],["5YU9_B_1E8B1101_1","2r4b","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","PF07714(Pkinase_Tyr)",6,"LYS A 751;MET A 772;LEU A 794;LEU A 850;THR A 860;ASP A 861","GW7 A   1 (-3.9A);GW7 A   1 ( 3.8A);GW7 A   1 (-4.1A);GW7 A   1 (-4.2A);GW7 A   1 (-3.5A);GW7 A   1 (-4.1A)","0.85A","5yu9B-2r4bA:37.5","5yu9B-2r4bA:18.38"],["5YU9_B_1E8B1101_1","2xk9","Homo sapiens","CHECKPOINT KINASE 2","PF00069(Pkinase)",6,"GLY A 227;VAL A 234;ALA A 247;ASP A 311;LEU A 354;THR A 367","XK9 A1511 ( 4.5A);XK9 A1511 (-4.8A);XK9 A1511 ( 4.1A);None;XK9 A1511 (-4.6A);XK9 A1511 (-3.7A)","0.58A","5yu9B-2xk9A:21.0","5yu9B-2xk9A:14.85"],["5YU9_B_1E8B1101_1","2y7j","Homo sapiens","PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS\/LIVER ISOFORM","PF00069(Pkinase)",6,"GLY A  31;VAL A  38;ALA A  51;LEU A 105;ASP A 117;LEU A 160","B49 A1294 (-4.0A);None;B49 A1294 (-3.2A);None;None;B49 A1294 (-4.4A)","0.73A","5yu9B-2y7jA:22.4","5yu9B-2y7jA:13.22"],["5YU9_B_1E8B1101_1","2z7r","Homo sapiens","RIBOSOMAL PROTEIN S6 KINASE ALPHA-1","PF00069(Pkinase)",6,"GLY A  69;VAL A  76;ALA A  92;LEU A 139;LEU A 194;THR A 204","STU A   1 (-3.3A);None;STU A   1 (-3.3A);None;STU A   1 (-4.6A);STU A   1 (-3.6A)","0.86A","5yu9B-2z7rA:22.4","5yu9B-2z7rA:12.77"],["5YU9_B_1E8B1101_1","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",6,"GLY A 202;VAL A 209;ALA A 220;ASP A 276;LEU A 321;ASP A 332","None","0.75A","5yu9B-3d7uA:24.5","5yu9B-3d7uA:19.23"],["5YU9_B_1E8B1101_1","3dak","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE OSR1","PF00069(Pkinase)",9,"GLY A  24;VAL A  31;ALA A  44;LYS A  46;MET A  67;LEU A  90;ASP A 102;LEU A 153;ASP A 164","ANP A   1 (-3.3A);ANP A   1 (-4.5A);ANP A   1 ( 3.9A);ANP A   1 (-2.8A);None;None;None;None;ANP A   1 (-3.8A)","0.98A","5yu9B-3dakA:22.8","5yu9B-3dakA:15.25"],["5YU9_B_1E8B1101_1","3dtc","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 9","PF07714(Pkinase_Tyr)",6,"GLY A 151;VAL A 158;ALA A 169;LEU A 218;LEU A 275;THR A 293","VIN A6331 (-3.5A);VIN A6331 (-4.7A);VIN A6331 (-3.4A);None;VIN A6331 (-4.5A);VIN A6331 (-3.6A)","0.65A","5yu9B-3dtcA:21.5","5yu9B-3dtcA:14.45"],["5YU9_B_1E8B1101_1","3dxn","Toxoplasma gondii","CALMODULIN-LIKE DOMAIN PROTEIN KINASE ISOFORM 3","PF00069(Pkinase)",6,"GLY A  30;VAL A  37;ALA A  50;LEU A  98;ASP A 110;ASP A 167","None","0.82A","5yu9B-3dxnA:24.8","5yu9B-3dxnA:14.98"],["5YU9_B_1E8B1101_1","3dxn","Toxoplasma gondii","CALMODULIN-LIKE DOMAIN PROTEIN KINASE ISOFORM 3","PF00069(Pkinase)",6,"VAL A  37;ALA A  50;LEU A  98;ASP A 110;LEU A 153;ASP A 167","None","0.73A","5yu9B-3dxnA:24.8","5yu9B-3dxnA:14.98"],["5YU9_B_1E8B1101_1","3f2a","Homo sapiens","PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE PIM-1","PF00069(Pkinase)",6,"GLY A  45;VAL A  52;ALA A  65;LEU A 118;ASP A 131;LEU A 174","985 A   1 ( 3.9A);985 A   1 (-4.5A);985 A   1 (-3.5A);None;None;985 A   1 (-4.8A)","0.85A","5yu9B-3f2aA:16.1","5yu9B-3f2aA:14.08"],["5YU9_B_1E8B1101_1","3fzp","Homo sapiens","PROTEIN TYROSINE KINASE 2 BETA","PF07714(Pkinase_Tyr)",6,"GLY A 432;VAL A 439;ALA A 455;LYS A 457;LEU A 556;ASP A 567","AGS A 999 ( 4.2A);AGS A 999 (-4.6A);AGS A 999 (-3.6A);AGS A 999 (-2.5A);AGS A 999 (-4.5A);AGS A 999 ( 3.9A)","0.85A","5yu9B-3fzpA:25.1","5yu9B-3fzpA:18.35"],["5YU9_B_1E8B1101_1","3i6u","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE CHK2","PF00069(Pkinase);PF00498(FHA)",6,"GLY A 227;VAL A 234;ALA A 247;LEU A 354;THR A 367;ASP A 368","None","0.76A","5yu9B-3i6uA:22.2","5yu9B-3i6uA:10.83"],["5YU9_B_1E8B1101_1","3kex","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3","PF07714(Pkinase_Tyr)",7,"GLY A 697;VAL A 704;LYS A 723;LEU A 766;ASP A 778;LEU A 822;ASP A 833","ANP A   1 (-3.7A);ANP A   1 (-3.9A);ANP A   1 (-3.4A);None;None;ANP A   1 (-4.7A); MG A1001 ( 3.1A)","0.83A","5yu9B-3kexA:35.1","5yu9B-3kexA:15.79"],["5YU9_B_1E8B1101_1","3lij","Cryptosporidium parvum","CALCIUM\/CALMODULIN DEPENDENT PROTEIN KINASE WITH A KINASE DOMAIN AND 4 CALMODULIN LIKE EF HANDS","PF00069(Pkinase);PF13499(EF-hand_7)",6,"GLY A  69;VAL A  76;ALA A  89;LYS A  91;LEU A 136;LEU A 191","ANP A 522 (-3.5A);ANP A 522 (-4.1A);ANP A 522 (-3.6A);ANP A 522 (-3.5A);None;ANP A 522 (-4.7A)","0.77A","5yu9B-3lijA:23.0","5yu9B-3lijA:9.92"],["5YU9_B_1E8B1101_1","3lzb","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",11,"GLY A 695;VAL A 702;ALA A 719;LYS A 721;MET A 742;LEU A 764;CYH A 773;ASP A 776;LEU A 820;THR A 830;ASP A 831","ITI A   1 ( 4.8A);ITI A   1 (-4.8A);ITI A   1 (-2.9A);ITI A   1 (-2.6A);ITI A   1 (-3.4A);ITI A   1 ( 4.2A);ITI A   1 (-4.8A);None;ITI A   1 (-4.6A);ITI A   1 (-3.8A);ITI A   1 ( 4.6A)","0.69A","5yu9B-3lzbA:38.9","5yu9B-3lzbA:95.00"],["5YU9_B_1E8B1101_1","3niz","Cryptosporidium parvum","RHODANESE FAMILY PROTEIN","PF00069(Pkinase)",6,"GLY A  30;VAL A  37;ALA A  49;LYS A  51;LEU A  96;LEU A 151","ADP A 314 (-3.3A);ADP A 314 (-4.0A);ADP A 314 (-3.5A);ADP A 314 (-2.8A);None;ADP A 314 (-4.6A)","0.89A","5yu9B-3nizA:22.6","5yu9B-3nizA:17.58"],["5YU9_B_1E8B1101_1","3nyo","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 6","PF00069(Pkinase);PF00615(RGS)",6,"GLY A 193;VAL A 200;ALA A 213;LYS A 215;LEU A 261;LEU A 318","AMP A 577 ( 3.7A);AMP A 577 (-4.3A);AMP A 577 (-3.4A);AMP A 577 (-2.8A);None;AMP A 577 (-4.8A)","0.81A","5yu9B-3nyoA:21.1","5yu9B-3nyoA:9.04"],["5YU9_B_1E8B1101_1","3pp0","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2","PF07714(Pkinase_Tyr)",8,"GLY A 727;VAL A 734;ALA A 751;LEU A 796;CYH A 805;ASP A 808;LEU A 852;THR A 862","None;03Q A   1 (-4.5A);03Q A   1 (-3.1A);03Q A   1 (-4.3A);None;None;03Q A   1 (-4.4A);03Q A   1 (-3.3A)","0.64A","5yu9B-3pp0A:34.9","5yu9B-3pp0A:59.82"],["5YU9_B_1E8B1101_1","3pp0","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2","PF07714(Pkinase_Tyr)",7,"GLY A 727;VAL A 734;ALA A 751;MET A 774;CYH A 805;ASP A 808;THR A 862","None;03Q A   1 (-4.5A);03Q A   1 (-3.1A);03Q A   1 (-4.5A);None;None;03Q A   1 (-3.3A)","1.37A","5yu9B-3pp0A:34.9","5yu9B-3pp0A:59.82"],["5YU9_B_1E8B1101_1","3pp0","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2","PF07714(Pkinase_Tyr)",7,"VAL A 734;ALA A 751;LEU A 796;CYH A 805;ASP A 808;LEU A 852;ASP A 863","03Q A   1 (-4.5A);03Q A   1 (-3.1A);03Q A   1 (-4.3A);None;None;03Q A   1 (-4.4A);03Q A   1 (-4.0A)","0.85A","5yu9B-3pp0A:34.9","5yu9B-3pp0A:59.82"],["5YU9_B_1E8B1101_1","3sxf","Toxoplasma gondii","CALMODULIN-DOMAIN PROTEIN KINASE 1","PF00069(Pkinase);PF13499(EF-hand_7)",7,"GLY A  58;VAL A  65;ALA A  78;LYS A  80;LEU A 126;LEU A 181;ASP A 195","BK5 A 701 ( 3.8A);BK5 A 701 (-4.2A);BK5 A 701 (-3.4A);BK5 A 701 (-3.5A);BK5 A 701 (-3.3A);None;BK5 A 701 (-4.0A)","0.70A","5yu9B-3sxfA:23.6","5yu9B-3sxfA:11.36"],["5YU9_B_1E8B1101_1","3sxs","Homo sapiens","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","PF07714(Pkinase_Tyr)",6,"GLY A 424;VAL A 431;ALA A 443;LYS A 445;CYH A 496;LEU A 543","PP2 A   1 ( 4.1A);PP2 A   1 (-4.5A);PP2 A   1 (-3.2A);PP2 A   1 (-4.5A);None;PP2 A   1 (-4.6A)","0.81A","5yu9B-3sxsA:23.6","5yu9B-3sxsA:18.02"],["5YU9_B_1E8B1101_1","3ulz","Arabidopsis thaliana","BRASSINOSTEROID INSENSITIVE 1-ASSOCIATED RECEPTOR KINASE 1","PF00069(Pkinase)",7,"GLY A 296;VAL A 303;ALA A 315;LYS A 317;LEU A 361;LEU A 423;ASP A 434","None","0.94A","5yu9B-3ulzA:21.5","5yu9B-3ulzA:15.44"],["5YU9_B_1E8B1101_1","3vn9","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","PF00069(Pkinase)",6,"GLY A  60;VAL A  67;ALA A  80;MET A 129;LEU A 186;ASP A 197","ANK A 401 (-3.4A);ANK A 401 (-4.3A);ANK A 401 (-3.0A);ANK A 401 (-3.7A);ANK A 401 ( 4.9A); MG A 402 ( 2.8A)","0.80A","5yu9B-3vn9A:24.0","5yu9B-3vn9A:12.54"],["5YU9_B_1E8B1101_1","3wig","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","PF00069(Pkinase)",7,"GLY A  76;VAL A  83;ALA A  96;LYS A  98;MET A 144;ASP A 153;LEU A 198","ANP A 401 ( 3.7A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);ANP A 401 (-2.7A);CHU A 403 (-3.8A);None;ANP A 401 (-4.8A)","1.27A","5yu9B-3wigA:23.3","5yu9B-3wigA:16.55"],["5YU9_B_1E8B1101_1","3wig","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","PF00069(Pkinase)",7,"GLY A  76;VAL A  83;ALA A  96;LYS A  98;MET A 144;LEU A 198;ASP A 209","ANP A 401 ( 3.7A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);ANP A 401 (-2.7A);CHU A 403 (-3.8A);ANP A 401 (-4.8A); MG A 402 (-3.2A)","0.81A","5yu9B-3wigA:23.3","5yu9B-3wigA:16.55"],["5YU9_B_1E8B1101_1","4agu","Homo sapiens","CYCLIN-DEPENDENT KINASE-LIKE 1","PF00069(Pkinase)",6,"GLY A  11;VAL A  18;ALA A  31;LYS A  33;LEU A  78;LEU A 133","D15 A 500 (-3.8A);D15 A 500 (-4.6A);D15 A 500 (-3.4A);D15 A 500 ( 4.1A);None;D15 A 500 (-4.5A)","0.65A","5yu9B-4aguA:22.4","5yu9B-4aguA:13.62"],["5YU9_B_1E8B1101_1","4c02","Homo sapiens","ACTIVIN RECEPTOR TYPE-1","PF00069(Pkinase);PF08515(TGF_beta_GS)",8,"GLY A 215;VAL A 222;ALA A 233;LYS A 235;LEU A 281;ASP A 293;LEU A 343;ASP A 354","None;TAK A1507 (-4.7A);TAK A1507 (-3.3A);TAK A1507 ( 4.5A);None;None;TAK A1507 (-4.7A);TAK A1507 (-3.5A)","0.87A","5yu9B-4c02A:25.0","5yu9B-4c02A:15.41"],["5YU9_B_1E8B1101_1","4c0t","Candida albicans","LIKELY PROTEIN KINASE","PF00069(Pkinase)",6,"GLY A 247;VAL A 254;ALA A 267;LEU A 371;THR A 381;ASP A 382","None","0.81A","5yu9B-4c0tA:20.6","5yu9B-4c0tA:7.37"],["5YU9_B_1E8B1101_1","4eqm","Staphylococcus aureus","PROTEIN KINASE","PF00069(Pkinase)",6,"GLY A  17;VAL A  24;ALA A  37;LYS A  39;LEU A  85;ASP A 151","ANP A 300 ( 4.4A);ANP A 300 ( 4.7A);ANP A 300 ( 3.8A);ANP A 300 (-3.1A);None;None","0.72A","5yu9B-4eqmA:23.4","5yu9B-4eqmA:14.53"],["5YU9_B_1E8B1101_1","4f4p","Homo sapiens","TYROSINE-PROTEIN KINASE SYK","PF07714(Pkinase_Tyr)",7,"GLY A 378;VAL A 385;ALA A 400;LYS A 402;LEU A 446;LEU A 501;ASP A 512","0SB A 701 (-3.6A);0SB A 701 (-4.0A);0SB A 701 (-3.3A);0SB A 701 ( 4.8A);None;0SB A 701 (-4.4A);0SB A 701 (-3.9A)","0.97A","5yu9B-4f4pA:25.5","5yu9B-4f4pA:45.71"],["5YU9_B_1E8B1101_1","4fie","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PAK 4","PF00069(Pkinase);PF00786(PBD)",6,"GLY A 328;VAL A 335;ALA A 348;LYS A 350;LEU A 447;ASP A 458","ANP A1001 (-4.4A);ANP A1001 (-4.7A);ANP A1001 (-3.6A);ANP A1001 (-3.0A);ANP A1001 (-4.7A);ANP A1001 (-2.7A)","0.84A","5yu9B-4fieA:21.8","5yu9B-4fieA:11.19"],["5YU9_B_1E8B1101_1","4fl3","Homo sapiens","TYROSINE-PROTEIN KINASE SYK","PF00017(SH2);PF07714(Pkinase_Tyr)",8,"GLY A 378;VAL A 385;ALA A 400;LYS A 402;MET A 424;LEU A 446;LEU A 501;ASP A 512","ANP A 701 ( 4.0A);ANP A 701 (-4.1A);ANP A 701 (-3.3A);ANP A 701 (-2.7A);None;None;ANP A 701 (-4.5A); MG A 702 ( 3.1A)","0.59A","5yu9B-4fl3A:24.8","5yu9B-4fl3A:7.85"],["5YU9_B_1E8B1101_1","4fl3","Homo sapiens","TYROSINE-PROTEIN KINASE SYK","PF00017(SH2);PF07714(Pkinase_Tyr)",7,"GLY A 378;VAL A 385;ALA A 400;LYS A 402;MET A 448;LEU A 501;ASP A 512","ANP A 701 ( 4.0A);ANP A 701 (-4.1A);ANP A 701 (-3.3A);ANP A 701 (-2.7A);ANP A 701 ( 3.7A);ANP A 701 (-4.5A); MG A 702 ( 3.1A)","0.84A","5yu9B-4fl3A:24.8","5yu9B-4fl3A:7.85"],["5YU9_B_1E8B1101_1","4gl9","Mus musculus","TYROSINE-PROTEIN KINASE","PF07714(Pkinase_Tyr)",6,"GLY A 856;VAL A 863;ALA A 880;LEU A 927;ASP A 939;LEU A 983","IZA A2001 ( 4.9A);None;IZA A2001 (-3.4A);None;None;IZA A2001 ( 4.7A)","0.89A","5yu9B-4gl9A:28.2","5yu9B-4gl9A:15.99"],["5YU9_B_1E8B1101_1","4hzs","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr);PF14604(SH3_9)",8,"GLY A 133;VAL A 140;ALA A 156;LYS A 158;MET A 181;ASP A 215;LEU A 259;ASP A 270","None","0.76A","5yu9B-4hzsA:31.3","5yu9B-4hzsA:13.99"],["5YU9_B_1E8B1101_1","4id7","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr)",7,"GLY A 133;VAL A 140;ALA A 156;LYS A 158;MET A 181;ASP A 215;LEU A 259","1G0 A 401 ( 4.2A);1G0 A 401 (-4.4A);1G0 A 401 (-3.6A);1G0 A 401 (-3.7A);1G0 A 401 (-4.0A);None;1G0 A 401 (-4.6A)","1.39A","5yu9B-4id7A:29.7","5yu9B-4id7A:15.60"],["5YU9_B_1E8B1101_1","4jrn","Toxoplasma gondii","RHOPTRY KINASE FAMILY PROTEIN","PF14531(Kinase-like)",7,"GLY A 259;VAL A 266;ALA A 279;LYS A 281;LEU A 354;MET A 356;LEU A 416","ANP A 601 (-3.4A);ANP A 601 (-4.1A);ANP A 601 ( 3.9A);ANP A 601 (-3.2A);None;ANP A 601 (-3.3A);ANP A 601 ( 4.9A)","0.96A","5yu9B-4jrnA:18.8","5yu9B-4jrnA:13.81"],["5YU9_B_1E8B1101_1","4k11","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",8,"GLY A 274;VAL A 281;ALA A 293;LYS A 295;MET A 314;ASP A 348;LEU A 393;ASP A 404","0J9 A 601 ( 4.0A);0J9 A 601 (-4.4A);0J9 A 601 (-3.3A);0J9 A 601 ( 4.7A);None;None;0J9 A 601 (-4.5A);0J9 A 601 (-3.1A)","0.61A","5yu9B-4k11A:32.7","5yu9B-4k11A:15.57"],["5YU9_B_1E8B1101_1","4ks8","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PAK 6","PF00069(Pkinase)",6,"GLY A 414;VAL A 421;ALA A 434;ASP A 491;LEU A 533;ASP A 544","B49 A 701 ( 4.3A);None;B49 A 701 (-3.2A);B49 A 701 ( 4.3A);B49 A 701 (-4.5A);B49 A 701 (-4.6A)","0.72A","5yu9B-4ks8A:23.2","5yu9B-4ks8A:14.19"],["5YU9_B_1E8B1101_1","4lgg","Gallus gallus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF07714(Pkinase_Tyr)",7,"GLY A 274;VAL A 281;ALA A 293;LYS A 295;ASP A 348;LEU A 393;ASP A 404","VGG A 601 ( 3.8A);VGG A 601 ( 3.5A);VGG A 601 (-3.5A);VGG A 601 (-3.8A);None;VGG A 601 (-4.5A);VGG A 601 ( 4.7A)","0.85A","5yu9B-4lggA:28.4","5yu9B-4lggA:18.80"],["5YU9_B_1E8B1101_1","4m69","Mus musculus","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 3","PF00069(Pkinase)",7,"GLY A  29;VAL A  36;ALA A  49;LYS A  51;LEU A  93;LEU A 150;ASP A 161","ANP A 401 (-3.8A);ANP A 401 (-4.5A);ANP A 401 (-3.1A);ANP A 401 (-2.9A);None;ANP A 401 (-4.8A); MG A 403 ( 3.1A)","0.76A","5yu9B-4m69A:26.5","5yu9B-4m69A:14.43"],["5YU9_B_1E8B1101_1","4m69","Mus musculus","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 3","PF00069(Pkinase)",7,"GLY A  29;VAL A  36;ALA A  49;LYS A  51;MET A  65;LEU A  93;LEU A 150","ANP A 401 (-3.8A);ANP A 401 (-4.5A);ANP A 401 (-3.1A);ANP A 401 (-2.9A);None;None;ANP A 401 (-4.8A)","1.00A","5yu9B-4m69A:26.5","5yu9B-4m69A:14.43"],["5YU9_B_1E8B1101_1","4ow8","Mycobacterium tuberculosis","SERINE\/THREONINE-PROTEIN KINASE PKNA","PF00069(Pkinase)",6,"VAL A  27;ALA A  40;LYS A  42;LEU A  93;THR A 158;ASP A 159","None","0.83A","5yu9B-4ow8A:23.7","5yu9B-4ow8A:15.06"],["5YU9_B_1E8B1101_1","4rgj","Plasmodium falciparum","CALCIUM-DEPENDENT PROTEIN KINASE 4","PF00069(Pkinase);PF13499(EF-hand_7)",6,"GLY A  77;VAL A  84;ALA A  97;LYS A  99;LEU A 145;ASP A 215","None","0.39A","5yu9B-4rgjA:23.2","5yu9B-4rgjA:10.40"],["5YU9_B_1E8B1101_1","4tnb","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 5","PF00069(Pkinase);PF00615(RGS)",6,"GLY A 193;VAL A 200;ALA A 213;LEU A 261;LEU A 318;ASP A 329","SGV A 601 (-3.4A);SGV A 601 ( 4.6A);SGV A 601 (-3.3A);None;SGV A 601 (-4.9A);SGV A 601 (-3.0A)","0.74A","5yu9B-4tnbA:19.7","5yu9B-4tnbA:9.85"],["5YU9_B_1E8B1101_1","4uya","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLK4","PF07714(Pkinase_Tyr)",6,"GLY A 131;VAL A 138;ALA A 149;LEU A 198;LEU A 270;THR A 288","AGS A1438 ( 3.8A);AGS A1438 (-4.4A);AGS A1438 (-3.4A);None;AGS A1438 (-4.7A);AGS A1438 ( 4.7A)","0.75A","5yu9B-4uyaA:26.0","5yu9B-4uyaA:16.00"],["5YU9_B_1E8B1101_1","4xi2","Mus musculus","TYROSINE-PROTEIN KINASE BTK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"GLY A 409;VAL A 416;ALA A 428;MET A 449;CYH A 481;LEU A 528;ASP A 539","None","0.88A","5yu9B-4xi2A:26.7","5yu9B-4xi2A:11.21"],["5YU9_B_1E8B1101_1","4y93","Bos taurus","NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE","PF00169(PH);PF00779(BTK);PF07714(Pkinase_Tyr)",6,"GLY A 409;VAL A 416;ALA A 428;CYH A 481;LEU A 528;ASP A 539","746 A 702 ( 3.5A);746 A 702 ( 4.3A);746 A 702 (-2.4A);None;746 A 702 (-4.4A);746 A 702 (-3.7A)","0.65A","5yu9B-4y93A:30.7","5yu9B-4y93A:10.73"],["5YU9_B_1E8B1101_1","4y93","Bos taurus","NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE","PF00169(PH);PF00779(BTK);PF07714(Pkinase_Tyr)",6,"VAL A 416;ALA A 428;MET A 449;CYH A 481;LEU A 528;ASP A 539","746 A 702 ( 4.3A);746 A 702 (-2.4A);None;None;746 A 702 (-4.4A);746 A 702 (-3.7A)","0.86A","5yu9B-4y93A:30.7","5yu9B-4y93A:10.73"],["5YU9_B_1E8B1101_1","4yc6","Homo sapiens","CYCLIN-DEPENDENT KINASE 1","PF00069(Pkinase)",7,"GLY A  11;VAL A  18;ALA A  31;LYS A  33;LEU A  78;LEU A 135;ASP A 146","None","0.68A","5yu9B-4yc6A:23.8","5yu9B-4yc6A:16.67"],["5YU9_B_1E8B1101_1","4yhj","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 4","PF00069(Pkinase);PF00615(RGS)",6,"GLY A 194;VAL A 201;ALA A 214;LYS A 216;LEU A 262;LEU A 319","AN2 A 601 (-3.4A);AN2 A 601 (-4.0A);AN2 A 601 (-3.6A);AN2 A 601 ( 3.9A);None;None","0.85A","5yu9B-4yhjA:19.7","5yu9B-4yhjA:9.45"],["5YU9_B_1E8B1101_1","4ynz","Mus musculus","SERINE\/THREONINE-PROTEIN KINASE BRSK2","PF00069(Pkinase)",7,"GLY A  27;VAL A  34;ALA A  47;LYS A  49;LEU A  94;LEU A 149;ASP A 160","None","0.71A","5yu9B-4ynzA:21.3","5yu9B-4ynzA:12.87"],["5YU9_B_1E8B1101_1","5dbx","Mus musculus","STE20\/SPS1-RELATED PROLINE-ALANINE-RICH PROTEIN KINASE","PF00069(Pkinase)",7,"GLY A  82;VAL A  89;ALA A 102;LYS A 104;LEU A 148;ASP A 160;LEU A 211","ANP A 401 ( 3.9A);ANP A 401 (-4.0A);ANP A 401 ( 4.0A);ANP A 401 (-3.0A);None;None;None","0.95A","5yu9B-5dbxA:22.2","5yu9B-5dbxA:14.55"],["5YU9_B_1E8B1101_1","5e8y","Homo sapiens","TGF-BETA RECEPTOR TYPE-2","PF07714(Pkinase_Tyr)",6,"GLY A 251;VAL A 258;ALA A 275;LYS A 277;LEU A 323;LEU A 386","STU A 601 (-2.9A);STU A 601 (-4.0A);STU A 601 (-3.1A);STU A 601 (-2.4A);None;STU A 601 (-3.9A)","0.68A","5yu9B-5e8yA:18.6","5yu9B-5e8yA:13.88"],["5YU9_B_1E8B1101_1","5eyk","Xenopus laevis","AURORA KINASE B-A","PF00069(Pkinase)",6,"GLY A 100;VAL A 107;ALA A 120;LYS A 122;LEU A 168;LEU A 223","5U5 A 401 (-3.8A);5U5 A 401 ( 4.3A);5U5 A 401 (-3.5A);5U5 A 401 (-2.6A);None;5U5 A 401 (-4.7A)","0.72A","5yu9B-5eykA:22.3","5yu9B-5eykA:15.30"],["5YU9_B_1E8B1101_1","5fm2","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET","PF07714(Pkinase_Tyr)",6,"GLY A 731;VAL A 738;ALA A 756;LYS A 758;LEU A 802;LEU A 881","PP1 A2012 ( 3.9A);PP1 A2012 (-4.4A);PP1 A2012 (-3.2A);PP1 A2012 (-4.1A);None;PP1 A2012 (-4.6A)","0.52A","5yu9B-5fm2A:29.0","5yu9B-5fm2A:14.29"],["5YU9_B_1E8B1101_1","5ig1","Salpingoeca rosetta","CAMK\/CAMK2 PROTEIN KINASE","PF00069(Pkinase)",6,"GLY A  25;VAL A  32;ALA A  45;LYS A  47;LEU A  92;THR A 160","None","0.87A","5yu9B-5ig1A:22.8","5yu9B-5ig1A:12.91"],["5YU9_B_1E8B1101_1","5j9z","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",9,"GLY A 719;VAL A 726;ALA A 743;LEU A 788;MET A 790;CYH A 797;ASP A 800;LEU A 844;THR A 854","6HJ A1101 ( 4.2A);6HJ A1101 ( 4.7A);6HJ A1101 (-3.1A);6HJ A1101 ( 4.6A);6HJ A1101 (-3.4A);6HJ A1101 (-1.6A);6HJ A1101 ( 4.1A);6HJ A1101 ( 4.8A);6HJ A1101 (-3.9A)","0.58A","5yu9B-5j9zA:35.8","5yu9B-5j9zA:95.00"],["5YU9_B_1E8B1101_1","5j9z","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",7,"GLY A 719;VAL A 726;ALA A 743;LYS A 745;LEU A 788;MET A 790;LEU A 844","6HJ A1101 ( 4.2A);6HJ A1101 ( 4.7A);6HJ A1101 (-3.1A);6HJ A1101 (-4.2A);6HJ A1101 ( 4.6A);6HJ A1101 (-3.4A);6HJ A1101 ( 4.8A)","0.66A","5yu9B-5j9zA:35.8","5yu9B-5j9zA:95.00"],["5YU9_B_1E8B1101_1","5j9z","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",9,"GLY A 719;VAL A 726;ALA A 743;MET A 790;CYH A 797;ASP A 800;LEU A 844;THR A 854;ASP A 855","6HJ A1101 ( 4.2A);6HJ A1101 ( 4.7A);6HJ A1101 (-3.1A);6HJ A1101 (-3.4A);6HJ A1101 (-1.6A);6HJ A1101 ( 4.1A);6HJ A1101 ( 4.8A);6HJ A1101 (-3.9A);6HJ A1101 (-4.3A)","0.74A","5yu9B-5j9zA:35.8","5yu9B-5j9zA:95.00"],["5YU9_B_1E8B1101_1","5jzn","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE DCLK1","PF00069(Pkinase)",6,"GLY A 397;VAL A 404;ALA A 417;LEU A 463;ASP A 475;LEU A 518","GUI A 701 ( 3.8A);GUI A 701 (-4.4A);GUI A 701 ( 3.9A);None;GUI A 701 (-4.1A);GUI A 701 (-4.4A)","0.61A","5yu9B-5jznA:22.4","5yu9B-5jznA:16.13"],["5YU9_B_1E8B1101_1","5kbr","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PAK 1","PF00069(Pkinase)",6,"GLY A 277;VAL A 284;ALA A 297;ASP A 354;LEU A 396;THR A 406","IPW A 601 ( 3.9A);IPW A 601 (-4.2A);IPW A 601 (-3.5A);None;IPW A 601 (-4.5A);IPW A 601 (-3.7A)","0.70A","5yu9B-5kbrA:21.7","5yu9B-5kbrA:17.15"],["5YU9_B_1E8B1101_1","5kbr","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PAK 1","PF00069(Pkinase)",6,"GLY A 277;VAL A 284;ALA A 297;LYS A 299;LEU A 396;THR A 406","IPW A 601 ( 3.9A);IPW A 601 (-4.2A);IPW A 601 (-3.5A);IPW A 601 (-4.5A);IPW A 601 (-4.5A);IPW A 601 (-3.7A)","0.61A","5yu9B-5kbrA:21.7","5yu9B-5kbrA:17.15"],["5YU9_B_1E8B1101_1","5lpy","Arabidopsis thaliana","PROTEIN BRASSINOSTEROID INSENSITIVE 1","PF00069(Pkinase)",7,"GLY A 890;VAL A 897;ALA A 909;LYS A 911;LEU A 954;LEU A1016;ASP A1027","ATP A1200 ( 4.6A);ATP A1200 ( 4.5A);ATP A1200 (-3.5A);ATP A1200 (-3.8A);None;ATP A1200 (-4.6A);ATP A1200 (-4.1A)","0.90A","5yu9B-5lpyA:22.0","5yu9B-5lpyA:16.60"],["5YU9_B_1E8B1101_1","5lpy","Arabidopsis thaliana","PROTEIN BRASSINOSTEROID INSENSITIVE 1","PF00069(Pkinase)",7,"GLY A 890;VAL A 897;LYS A 911;LEU A 954;ASP A 966;LEU A1016;ASP A1027","ATP A1200 ( 4.6A);ATP A1200 ( 4.5A);ATP A1200 (-3.8A);None;ATP A1200 (-3.9A);ATP A1200 (-4.6A);ATP A1200 (-4.1A)","1.04A","5yu9B-5lpyA:22.0","5yu9B-5lpyA:16.60"],["5YU9_B_1E8B1101_1","5lpz","Arabidopsis thaliana","PROTEIN BRASSINOSTEROID INSENSITIVE 1","PF00069(Pkinase)",8,"GLY A 890;VAL A 897;ALA A 909;LYS A 911;LEU A 954;ASP A 966;LEU A1016;ASP A1027","ADP A1200 ( 4.0A);ADP A1200 (-4.4A);ADP A1200 (-3.5A);ADP A1200 ( 4.3A);None;ADP A1200 (-4.2A);ADP A1200 (-4.7A);ADP A1200 (-3.4A)","1.03A","5yu9B-5lpzA:22.2","5yu9B-5lpzA:13.66"],["5YU9_B_1E8B1101_1","5m09","Mycobacterium tuberculosis","SERINE\/THREONINE-PROTEIN KINASE PKNI","PF00069(Pkinase)",6,"GLY A  19;VAL A  26;ALA A  39;LYS A  41;MET A  89;ASP A 159","None","0.78A","5yu9B-5m09A:21.3","5yu9B-5m09A:13.28"],["5YU9_B_1E8B1101_1","5ncl","Saccharomyces cerevisiae","SERINE\/THREONINE-PROTEIN KINASE CBK1","no annotation",6,"GLY A 359;VAL A 366;ALA A 379;LYS A 381;LEU A 427;LEU A 482","ANP A 801 ( 4.1A);ANP A 801 (-4.7A);ANP A 801 ( 3.9A);ANP A 801 (-2.6A);None;ANP A 801 (-4.8A)","0.68A","5yu9B-5nclA:19.0","5yu9B-5nclA:21.51"],["5YU9_B_1E8B1101_1","5tur","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PIM-1","no annotation",6,"GLY A  45;VAL A  52;ALA A  65;LEU A 118;ASP A 131;LEU A 174","None;7LK A 401 (-4.9A);7LK A 401 (-3.3A);None;7LK A 401 (-3.0A);7LK A 401 (-4.8A)","0.84A","5yu9B-5turA:21.9","5yu9B-5turA:11.41"],["5YU9_B_1E8B1101_1","5vef","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PAK 4","no annotation",7,"GLY A 328;VAL A 335;ALA A 348;LYS A 350;MET A 395;LEU A 447;ASP A 458","M77 A 601 (-3.4A);M77 A 601 (-4.5A);M77 A 601 ( 3.5A);M77 A 601 ( 4.7A);M77 A 601 ( 2.9A);M77 A 601 (-4.6A);M77 A 601 ( 3.5A)","1.20A","5yu9B-5vefA:22.7","5yu9B-5vefA:13.29"],["5YU9_B_1E8B1101_1","5wno","Caenorhabditis elegans","RECEPTOR TYROSINE-PROTEIN KINASE LET-23","no annotation",7,"GLY A 892;VAL A 899;ALA A 917;LYS A 919;MET A 938;THR A1027;ASP A1028","ANP A1201 ( 3.8A);ANP A1201 (-4.4A);ANP A1201 (-3.3A);ANP A1201 (-3.8A);None;ANP A1201 ( 4.9A); MG A1202 ( 3.0A)","0.94A","5yu9B-5wnoA:34.6","5yu9B-5wnoA:42.68"],["5YU9_B_1E8B1101_1","5wno","Caenorhabditis elegans","RECEPTOR TYROSINE-PROTEIN KINASE LET-23","no annotation",7,"GLY A 892;VAL A 899;ALA A 917;MET A 938;LEU A1017;THR A1027;ASP A1028","ANP A1201 ( 3.8A);ANP A1201 (-4.4A);ANP A1201 (-3.3A);None;ANP A1201 (-4.7A);ANP A1201 ( 4.9A); MG A1202 ( 3.0A)","0.77A","5yu9B-5wnoA:34.6","5yu9B-5wnoA:42.68"],["5YU9_B_1E8B1101_1","5xd6","Arabidopsis thaliana","PROTEIN KINASE SUPERFAMILY PROTEIN","no annotation",6,"GLY A  76;VAL A  83;ALA A  95;LYS A  97;LEU A 139;LEU A 206","ANP A1000 ( 3.8A);ANP A1000 (-4.1A);ANP A1000 (-3.2A);ANP A1000 (-2.8A);None;ANP A1000 (-4.5A)","0.70A","5yu9B-5xd6A:23.9","5yu9B-5xd6A:29.21"],["5YU9_B_1E8B1101_1","5xd6","Arabidopsis thaliana","PROTEIN KINASE SUPERFAMILY PROTEIN","no annotation",6,"GLY A  76;VAL A  83;LYS A  97;LEU A 139;ASP A 151;LEU A 206","ANP A1000 ( 3.8A);ANP A1000 (-4.1A);ANP A1000 (-2.8A);None;ANP A1000 ( 4.9A);ANP A1000 (-4.5A)","0.59A","5yu9B-5xd6A:23.9","5yu9B-5xd6A:29.21"],["5YU9_B_1E8B1101_1","5xzw","Saccharomyces cerevisiae","SERINE\/THREONINE-PROTEIN KINASE RAD53","no annotation",6,"GLY A 205;VAL A 212;ALA A 225;LEU A 326;THR A 338;ASP A 339","None","0.75A","5yu9B-5xzwA:18.7","5yu9B-5xzwA:10.40"],["5YU9_B_1E8B1101_1","6ao5","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 3","no annotation",6,"GLY A  34;VAL A  41;ALA A  54;LYS A  56;MET A  74;ASP A 164","ANP A 501 ( 3.9A);ANP A 501 (-4.4A);ANP A 501 ( 3.7A);ANP A 501 (-2.4A);None; MG A 502 ( 3.1A)","0.87A","5yu9B-6ao5A:23.4","5yu9B-6ao5A:13.95"],["5YU9_B_1E8B1101_1","6ao5","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 3","no annotation",7,"GLY A  34;VAL A  41;ALA A  54;LYS A  56;MET A  99;LEU A 153;ASP A 164","ANP A 501 ( 3.9A);ANP A 501 (-4.4A);ANP A 501 ( 3.7A);ANP A 501 (-2.4A);ANP A 501 (-2.5A);ANP A 501 (-4.6A); MG A 502 ( 3.1A)","0.75A","5yu9B-6ao5A:23.4","5yu9B-6ao5A:13.95"],["5YU9_B_1E8B1101_1","6bfn","Homo sapiens","INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 1","no annotation",6,"GLY A 219;VAL A 226;ALA A 237;LEU A 286;LEU A 347;ASP A 358","DL1 A 601 ( 4.1A);None;DL1 A 601 (-3.4A);None;DL1 A 601 (-3.9A);DL1 A 601 (-3.1A)","0.60A","5yu9B-6bfnA:22.9","5yu9B-6bfnA:29.07"],["5YU9_B_1E8B1101_1","6eqi","Pediculus humanus","SERINE\/THREONINE-PROTEIN KINASE PINK1, PUTATIVE","no annotation",6,"VAL C 173;ALA C 191;LEU C 288;LEU C 341;THR C 356;ASP C 357","None","0.60A","5yu9B-6eqiC:20.4","5yu9B-6eqiC:12.56"],["5YU9_B_1E8B1101_1","6f3d","Homo sapiens","INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4","no annotation",6,"GLY A 193;VAL A 200;ALA A 211;LEU A 260;ASP A 272;LEU A 318","CJT A 502 ( 3.9A);CJT A 502 ( 4.8A);CJT A 502 (-3.4A);None;CJT A 502 (-3.3A);CJT A 502 (-4.7A)","0.60A","5yu9B-6f3dA:22.4","5yu9B-6f3dA:26.14"]]